Recent CGEM News
- Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager • GlobeNewswire Inc. • 05/26/2026 11:00:00 AM
- Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia • GlobeNewswire Inc. • 05/19/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 09:30:08 PM
- Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress • GlobeNewswire Inc. • 05/18/2026 09:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:08:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:03:38 AM
- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 09:00:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 08:34:54 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 04/28/2026 11:52:27 AM
- U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations • Business Wire • 04/28/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 10:54:21 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 10:50:13 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 10:46:38 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/10/2026 11:34:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/10/2026 11:26:44 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 11:23:20 AM
- Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/10/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:00:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:31:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 10:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 10:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 10:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 10:00:02 PM
